Our top pick for
Building a portfolio
United-Guardian, Inc is a household & personal products business based in the US. United-Guardian shares (UG) are listed on the NASDAQ and all prices are listed in US Dollars. United-Guardian employs 22 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$12.71 - $17.46|
|50-day moving average||$14.83|
|200-day moving average||$14.54|
|Wall St. target price||N/A|
|Dividend yield||$0.78 (5.21%)|
|Earnings per share (TTM)||$0.72|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing United-Guardian stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of United-Guardian's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
United-Guardian's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, United-Guardian shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
United-Guardian's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.8 million.
The EBITDA is a measure of a United-Guardian's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$11 million|
|Operating margin TTM||33.1%|
|Gross profit TTM||$6.1 million|
|Return on assets TTM||18.72%|
|Return on equity TTM||31.5%|
|Market capitalisation||$71.8 million|
TTM: trailing 12 months
There are currently 4,791 United-Guardian shares held short by investors – that's known as United-Guardian's "short interest". This figure is 39.6% up from 3,432 last month.
There are a few different ways that this level of interest in shorting United-Guardian shares can be evaluated.
United-Guardian's "short interest ratio" (SIR) is the quantity of United-Guardian shares currently shorted divided by the average quantity of United-Guardian shares traded daily (recently around 8555.3571428571). United-Guardian's SIR currently stands at 0.56. In other words for every 100,000 United-Guardian shares traded daily on the market, roughly 560 shares are currently held short.
However United-Guardian's short interest can also be evaluated against the total number of United-Guardian shares, or, against the total number of tradable United-Guardian shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case United-Guardian's short interest could be expressed as 0% of the outstanding shares (for every 100,000 United-Guardian shares in existence, roughly 0 shares are currently held short) or 0.0015% of the tradable shares (for every 100,000 tradable United-Guardian shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against United-Guardian.
Find out more about how you can short United-Guardian stock.
Dividend payout ratio: 1.15% of net profits
Recently United-Guardian has paid out, on average, around 1.15% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.21% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), United-Guardian shareholders could enjoy a 5.21% return on their shares, in the form of dividend payments. In United-Guardian's case, that would currently equate to about $0.78 per share.
While United-Guardian's payout ratio might seem low, this can signify that United-Guardian is investing more in its future growth.
United-Guardian's most recent dividend payout was on 7 December 2020. The latest dividend was paid out to all shareholders who bought their shares by 29 November 2020 (the "ex-dividend date").
United-Guardian's shares were split on a 6:5 basis on 11 September 1985. So if you had owned 5 shares the day before before the split, the next day you'd have owned 6 shares. This wouldn't directly have changed the overall worth of your United-Guardian shares – just the quantity. However, indirectly, the new 16.7% lower share price could have impacted the market appetite for United-Guardian shares which in turn could have impacted United-Guardian's share price.
Over the last 12 months, United-Guardian's shares have ranged in value from as little as $12.7091 up to $17.4607. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while United-Guardian's is 0.139. This would suggest that United-Guardian's shares are less volatile than average (for this exchange).
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products in the United States and internationally. It offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. The company's medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. Its pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder. The company's industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based cleanser. It also conducts research and development, primarily related to the development of cosmetic ingredients.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.